ZBH Zimmer Biomet
FY2025 10-K
Zimmer Biomet (ZBH) filed its fiscal year 2025 10-K annual report with the SEC on Feb 20, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model not detailed in this section; focuses on corporate governance and compliance policies
- • Adoption of Zimmer Biomet Code of Ethics for CEO and senior financial officers, publicly accessible online
Management Discussion & Analysis
- • Revenue $8,231.5M in 2025, up 7.2% YoY from $7,678.6M, driven by Paragon 28 acquisition (+2.5%), market growth, and currency effects (+0.8%)
- • Operating margin 13.3% in 2025 vs 16.7% in 2024, decline due to inventory charges (~$170M), acquisition/integration costs, tariffs, and higher compensation
Risk Factors
- • Cybersecurity risk oversight by Audit Committee with immediate escalation of material incidents to board
- • Potential operational disruption from evolving global cybersecurity threats monitored by specialized global security team
Financial SummaryXBRL
Revenue
$8.2B
Net Income
$705M
Operating Margin
13.3%
Net Margin
8.6%
ROE
5.6%
Total Assets
$23.1B
EPS (Diluted)
$3.55
Operating Cash Flow
$1.7B
Source: XBRL data from Zimmer Biomet FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Zimmer Biomet Annual Reports
Get deeper insights on Zimmer Biomet
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.